Vimarsana
Biggest News Aggregation in the World

Virtual Plenary News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Virtual Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Virtual Plenary Today - Breaking & Trending Today

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting - Vimarsana News

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

GSK granted EC marketing authorisation for Jemperli plus chemotherapy - Vimarsana News

GSK granted EC marketing authorisation for Jemperli plus chemotherapy

GSK granted EC marketing authorisation for Jemperli plus chemotherapy

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - Vimarsana News

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows...

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS - Vimarsana News

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231. "We are excited about our pipeline progress and our...

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer - Vimarsana News

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...